Inclusion criteria: (1) aged 40–75 years; (2) diagnosed with HT and CSVD; (3) TCM syndrome differentiation is Qi deficiency and blood stasis (QDBS), and the score of QDBS ≥ 5; (4) taking basic AHD, including calcium channel blockers (CCB), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB); (5) voluntarily signed informed consent form (ICF) to participate in this trial. Here, ACE is linked to hematocrit.